Company Overview and News


Add SRX
to your dashboard

Headline News

ASX 200 Index falls for a second day; Myer shares rise

2017-09-14 theage.com.au
The Australian sharemarket fell for a second day, as Myer's results showed the gloomy mood undermining the discretionary retail sector appears unmoved despite robust employment conditions in the economy.

ASX 200 Index falls for a second day; Myer shares rise

2017-09-14 smh.com.au
The Australian sharemarket fell for a second day, as Myer's results showed the gloomy mood undermining the discretionary retail sector appears unmoved despite robust employment conditions in the economy.

Finance news you need to know today

2017-07-31 perthnow.com.au
THE Australian market looks set to open flat, ahead of the Reserve Bank of Australia’s interest rate announcement, after the Dow hit a record high but selling in the tech giants pulled the Nasdaq down. At 0700 AEST on Tuesday, the share price futures index was down one point, or 0.02 per cent, at 5,660.

Two class actions loom for Sirtex

2017-07-31 businessnews.com.au
Sirtex Medical is facing two class actions over allegations the biotech company engaged in misleading and deceptive conduct in relation to missed sales forecasts for 2016/17 that sparked a share price plunge.

Nieuw onderzoek presenteert gegevens over eerstelijnsbehandeling met SIR-Spheres® Y-90-harsmicrosferen voor patiënten met levermetastasen als gevolg van rechtzijdig primaire (RSP)-darmkanker

2017-07-06 prnewswire
De algemene SIRFLOX -en FOXFIRE Global-bevindingen stellen dat toevoeging van levergerichte selectieve inwendige radiotherapie (SIRT) aan de standaard eerstelijnsbehandeling met chemotherapie de algehele overleving (OS) van patiënten met metastatisch colorectaalcarcinoom (mCRC) met rechts gelokaliseerde primaire tumoren kan verbeteren in vergelijking met patiënten die alleen chemotherapie ondergaan  

Sirtex Medical Release: New Analysis Reveals First-Line Treatment Data On SIR-Spheres Y-90 Resin Microspheres For Patients With Liver Metastases From Right-Sided Primary Colon Cancer

2017-07-05 devicespace
SIRFLOX and FOXFIRE Global findings suggest that adding liver-directed Selective Internal Radiation Therapy (SIRT) to standard first-line chemotherapy may improve overall survival in metastatic colorectal cancer (mCRC) patients with right-sided primary tumours, compared to those receiving chemotherapy alone   

New Analysis Reveals First-Line Treatment Data on SIR-Spheres® Y-90 Resin Microspheres for Patients with Liver Metastases from Right-Sided Primary Colon Cancer

2017-07-03 prnewswire
SIRFLOX and FOXFIRE Global findings suggest that adding liver-directed Selective Internal Radiation Therapy (SIRT) to standard first-line chemotherapy may improve overall survival in metastatic colorectal cancer (mCRC) patients with right-sided primary tumours, compared to those receiving chemotherapy alone   

Iron ore surge sparks miner rally on ASX

2017-06-28 theage.com.au
The ASX shook off early wobbles on Wednesday to push higher, led by strong gains in the miners after commodity prices rose overnight, despite comments from central bankers rattling global investors.

Iron ore surge sparks miner rally on ASX

2017-06-28 smh.com.au
The ASX shook off early wobbles on Wednesday to push higher, led by strong gains in the miners after commodity prices rose overnight, despite comments from central bankers rattling global investors.

Annual Financial Report

2017-06-13 londonstockexchange
In accordance with the Listing Rule 9.6.1, copies of the following documents have been submitted to the UK Listing Authority and will shortly be available for inspection via the National Storage Mechanism at http://www.morningstar.co.uk/uk/NSM

Uit nieuw onderzoek in Azië-Pacific is gebleken dat de behandeling van gevorderd HCC met SIR-Spheres® Y-90 harsmicrosferen geen significant verschil in totale overleving (OS) oplevert in vergelijking met de behandeling met Sorafenib, maar wel signif

2017-06-12 prnewswire
De eindresultaten van het SIRveNIB-onderzoek werden gepresenteerd op de 2017 jaarlijkse vergadering van de American Society of Clinical Oncology (ASCO)

Ergebnisse einer neuen asiatisch-pazifische Studie belegen: SIR-Spheres® Y-90 Harz-Mikrosphären zeigen verglichen mit Sorafenib keinen signifikanten Unterschied im Gesamtüberleben bei fortgeschrittenem HCC, jedoch signifikant weniger schwere Nebenwi

2017-06-08 prnewswire
Abschließende Ergebnisse der SIRveNIB-Studie wurden auf der diesjährigen Jahrestagung der American Society of Clinical Oncology (ASCO) vorgestellt

El estudio REsect muestra que los pacientes con cáncer colorrectal metastásico tratados en primera línea con las micro esferas de resina Y-90 SIR-Spheres® tienen más probabilidades de convertirse en candidatos para una cirugía hepática potencialment

2017-05-24 prnewswire
La evaluación ciega por parte de los cirujanos de los escaneos de tomografía computarizada antes y después del tratamiento de pacientes con metástasis de cáncer hepático colorrectal previamente no resecables, tratados en el estudio SIRFLOX, se presenta en la 12 Reunión Anual Europea-Africana de HPB

Sirtex Medical Release: Metastatic Colorectal Cancer Patients Treated First-Line With SIR-Spheres Y-90 Resin Microspheres More Likely To Become Candidates For Potentially Curative Liver Surgery, Resect Study Shows

2017-05-24 devicespace
Surgeons' blinded assessment of pre- and post-treatment CT scans of patients with previously unresectable colorectal cancer liver metastases treated in the SIRFLOX study presented at 12th Annual European-African HPB meeting

El estudio REsect demuestra que los pacientes afectados de cáncer colorrectal metastásico tratados en primera línea con microesferas de resina SIR-Spheres® Y-90 tienen una mayor probabilidad de convertirse en candidatos para una cirugía hepática pot

2017-05-24 prnewswire
Una evaluación ciega de cortes de CT hecha por cirujanos, antes y después del tratamiento de pacientes con metástasis hepáticas de cáncer colorrectal previamente no operables en el estudio SIRFLOX, se presentó en el 12º Congreso anual de la European-African HPB Association

Metastatic Colorectal Cancer Patients Treated First-line With SIR-Spheres® Y-90 Resin Microspheres More Likely to Become Candidates for Potentially Curative Liver Surgery, REsect Study Shows

2017-05-24 prnewswire
Surgeons' blinded assessment of pre- and post-treatment CT scans of patients with previously unresectable colorectal cancer liver metastases treated in the SIRFLOX study presented at 12th Annual European-African HPB meeting

American Society of Clinical Oncology (ASCO) Publishes Abstract of SIRveNIB, an Investigator-led Asia Pacific Primary Liver Cancer Study to be Presented at ASCO Annual Meeting in Chicago, 4 June 2017

2017-05-18 prnewswire
The SIRveNIB abstract published on-line in the Journal of Clinical Oncology states that treatment of locally advanced Hepatocellular Carcinoma (HCC) with a single treatment of SIR-Spheres® Y-90 resin microspheres results in Overall Survival not significantly different from twice-daily oral sorafenib, but with significantly better tumour response and fewer and less severe adverse events

ASX tumbles for second day as Trump trade turns toxic

2017-05-18 theage.com.au
Shares tumbled for a second session on Thursday in a sign investors may finally be shedding their complacency in regards to the potential fallout from the rolling controversies surrounding US president Donald Trump.

ASX tumbles for second day as Trump trade turns toxic

2017-05-18 smh.com.au
Shares tumbled for a second session on Thursday in a sign investors may finally be shedding their complacency in regards to the potential fallout from the rolling controversies surrounding US president Donald Trump.

Erhebliche Verbesserung der Überlebensqualität bei primärem Leberkrebs durch SIR-Spheres® Y-90 Harz-Mikrosphären

2017-05-05 prnewswire
Die SARAH Studie mit 459 Patienten zeigt, dass die lokale Therapie des fortgeschrittenen, inoperablen hepatozellulären Karzinoms (HCC) mit SIR-Spheres Y-90 Harz-Mikrosphären im Vergleich zu einer täglichen systemischen Standardtherapie mit Sorafenib nicht zum gewünschten Vorteil hinsichtlich der Gesamtüberlebensdauer geführt hat, jedoch eine signifikante Reduzierung der Nebenwirkungen und eine bessere Lebensqualität erreicht wurden